Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
Phase of Trial: Phase 0
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Roflumilast (Primary) ; Prednisone
- Indications Haematological malignancies
- Focus Adverse reactions
- 19 Aug 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 Apr 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016, according to ClinicalTrials.gov record.